STOCK TITAN

Humacyte Inc - HUMA STOCK NEWS

Welcome to our dedicated news page for Humacyte (Ticker: HUMA), a resource for investors and traders seeking the latest updates and insights on Humacyte.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Humacyte's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Humacyte's position in the market.

Rhea-AI Summary
HUMA: Positive top line results from the V005 Phase 2/3 trial of the Human Acellular Vessel™ (HAV™) in vascular trauma repair. BLA for an indication in vascular trauma planned to be filed with the FDA during the current quarter. Financial results for the third quarter ended September 30, 2023. Third Quarter 2023 Financial Highlights: $100.0 million cash and cash equivalents as of September 30, 2023. No revenue for the third quarter of 2023. Research and development expenses were $18.6 million for the third quarter of 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.33%
Tags
-
Rhea-AI Summary
Humacyte, Inc. (Nasdaq: HUMA) will release its financial results for the third quarter ended September 30, 2023, on November 9, 2023. A webcast and conference call will be held at 4:30 p.m. ET to provide a corporate and financial update. Dial-in details: 1-888-999-5318 (U.S.) and 1-848-280-6460 (International). Webcast link available on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.21%
Tags
conferences earnings
-
Rhea-AI Summary
Humacyte to present at Cantor Global Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.71%
Tags
conferences
Rhea-AI Summary
Humacyte to host KOL event discussing clinical data from Phase 2/3 V005 trial and use of Human Acellular Vessel™ (HAV™) in repairing blood vessels.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.66%
Tags
conferences
-
Rhea-AI Summary
Humacyte announces positive top line results from its V005 Phase 2/3 trial of the Human Acellular Vessel (HAV) in vascular trauma repair. The trial showed higher rates of patency, lower rates of amputation and infection compared to synthetic graft benchmarks. BLA planned to be filed with FDA in 4th Quarter 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.86%
Tags
-
Rhea-AI Summary
Humacyte, Inc. to announce top line data results from Phase 2/3 V005 vascular trauma clinical trial in virtual webinar. HAV receives priority designation for treatment of vascular trauma.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.86%
Tags
Rhea-AI Summary
Humacyte announces positive results from clinical study on HAV for arterial bypass and limb salvage in patients with CLTI
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.37%
Tags
-
Rhea-AI Summary
Humacyte presented clinical outcomes of its Human Acellular Vessel (HAV) in Ukraine, showing high success rates in treating traumatic vascular injuries. The HAV had a 30-day patency rate of 95% and a limb salvage rate of 100%. No amputations or infections were reported. The data will be included in the Biologics License Application (BLA) planned for Q4 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.89%
Tags
none
-
Rhea-AI Summary
Humacyte completes enrollment in Phase 2/3 trial of HAV in vascular trauma repair, with top-line results expected in Q3 2023. Enrollment in Phase 3 trial of HAV in hemodialysis access also completed. Results from humanitarian program in Ukraine show high success rates. Preclinical study demonstrates HAV's infection resistance. Collaboration with JDRF to advance development of Biovascular Pancreas for type 1 diabetes. Cash and cash equivalents at $114.6 million as of June 30, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
23.55%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.9%
Tags
conferences earnings
Humacyte Inc

Nasdaq:HUMA

HUMA Rankings

HUMA Stock Data

342.96M
81.64M
31.42%
15.27%
3.35%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States
Durham

About HUMA

biotechnology company